{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:16:28Z","timestamp":1777382188543,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2012,8,28]],"date-time":"2012-08-28T00:00:00Z","timestamp":1346112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Am J Alzheimers Dis Other Demen"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:p>To better understand responses in the large number of US-based patients included in a global trial of donepezil 23 mg\/d versus 10 mg\/d for moderate-to-severe Alzheimer\u2019s disease (AD), post hoc exploratory analyses were performed to assess the efficacy and safety in US and non-US (rest of the world [RoW]) patient subgroups. In both subgroups, donepezil 23 mg\/d was associated with significantly greater cognitive benefits than donepezil 10 mg\/d. Significant global function benefits of donepezil 23 mg\/d over 10 mg\/d were also observed in the US subgroup only. Compared with RoW patients, US patients had relatively more severe AD, had been treated with donepezil 10 mg\/d for longer periods prior to the start of the study, and a higher proportion took concomitant memantine. In both subgroups, donepezil had acceptable tolerability; overall incidence of treatment-emergent adverse events was higher in patients receiving donepezil 23 mg\/d compared with donepezil 10 mg\/d.<\/jats:p>","DOI":"10.1177\/1533317512454708","type":"journal-article","created":{"date-parts":[[2012,8,28]],"date-time":"2012-08-28T08:03:03Z","timestamp":1346140983000},"page":"421-432","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":22,"title":["Subgroup Analysis of US and Non-US Patients in a Global Study of High-Dose Donepezil (23 mg) in Moderate and Severe Alzheimer\u2019s Disease"],"prefix":"10.1177","volume":"27","author":[{"given":"Stephen","family":"Salloway","sequence":"first","affiliation":[{"name":"Brown Alpert Medical School, Providence, RI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacobo","family":"Mintzer","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Research & Clinical Programs, Medical University of South Carolina, North Charleston, SC, USA"},{"name":"Ralph H Johnson VA Medical Center, Charleston, SC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey L.","family":"Cummings","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Geldmacher","sequence":"additional","affiliation":[{"name":"Division of Memory Disorders and Behavioral Neurology, University of Alabama-Birmingham, Birmingham, AL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijun","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Biometrics, Eisai Inc., Woodcliff Lake, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Yardley","sequence":"additional","affiliation":[{"name":"Neuroscience Product Creation Unit, Eisai Ltd, European Knowledge Centre, Hatfield, Hertfordshire, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Mackell","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2012,8,28]]},"reference":[{"key":"bibr1-1533317512454708","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000266627.96040.5a"},{"key":"bibr2-1533317512454708","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.4.613"},{"key":"bibr3-1533317512454708","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.12.1852"},{"key":"bibr4-1533317512454708","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.3.489"},{"key":"bibr5-1533317512454708","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68350-5"},{"key":"bibr6-1533317512454708","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.06.019"},{"key":"bibr7-1533317512454708","unstructured":"FDA Center for Drug Evaluation and Research. Summary Review for Aricept (donepezil hydrochloride extended release) 23 mg Sustained Release. 2012."},{"key":"bibr8-1533317512454708","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7091-6139-5_14"},{"key":"bibr9-1533317512454708","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-11-21"},{"key":"bibr10-1533317512454708","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2005.072306"},{"key":"bibr11-1533317512454708","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.9.1942"},{"key":"bibr12-1533317512454708","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2009.12.003"},{"key":"bibr13-1533317512454708","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.9.1306"},{"key":"bibr14-1533317512454708","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050151"},{"issue":"127","key":"bibr15-1533317512454708","first-page":"45","author":"Inglis F.","year":"2002","journal-title":"Int J Clin Pract Suppl"},{"key":"bibr16-1533317512454708","doi-asserted-by":"publisher","DOI":"10.1177\/1533317510372923"},{"key":"bibr17-1533317512454708","doi-asserted-by":"publisher","DOI":"10.1177\/1533317509352334"},{"key":"bibr18-1533317512454708","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.65.6_suppl_3.S10"},{"key":"bibr19-1533317512454708","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(01)01872-9"}],"container-title":["American Journal of Alzheimer's Disease &amp; Other Dementias\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1533317512454708","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1533317512454708","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1533317512454708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:23:05Z","timestamp":1777368185000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1533317512454708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,28]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1177\/1533317512454708"],"URL":"https:\/\/doi.org\/10.1177\/1533317512454708","relation":{},"ISSN":["1533-3175","1938-2731"],"issn-type":[{"value":"1533-3175","type":"print"},{"value":"1938-2731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,28]]}}}